BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
This highly advanced composite material features doxorubicin and small interfering RNA co-loaded lipid-enveloped mesoporous silica nanoparticles (CLMSNs-SS-NH2@DOX/siRNA) designed with an organic-inorganic hybrid core-shell architecture. The internal core structure consists of amino-functionalized, disulfide-linked mesoporous silica nanoparticles (CLMSNs-SS-NH2) that co-adsorb hydrophilic doxorubicin (DOX) hydrochloride and small interfering RNA (siRNA) fragments within their porous matrix, which is completely enclosed by a self-assembled outer shell of a phospholipid bilayer matrix. This complex configuration combines the rigid loading capacity and reduction-responsive cleavage parameters of a modified silica core with the interfacial stability and retention properties of a lipid bilayer shell. The resulting hybrid nanoparticles exhibit exceptional physical stability against cargo leakage and gravitational sedimentation.
Source
Custom synthesis
Functional Group
Doxorubicin; RNA; Mesoporous silica
Form
Solid or powder
Purity
≥95%
Impurities
No visible impurities to the naked eye.
Identity
HPLC/MS/NMR
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.